FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092617122> ?p ?o ?g. }

• W3092617122 endingPage "749" @default.
• W3092617122 startingPage "741" @default.
• W3092617122 abstract "Abstract Introduction Nephrotoxicity is a potential adverse effect of anticancer treatment in childhood. Cytostatics, abdominal radiotherapy, total body irradiation (TBI) and some agents used in supportive care may induce acute kidney injury (AKI) or lead to chronic kidney disease (CKD). The aim of this study was to test the hypothesis whether urinary kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) are increased in acute lymphoblastic leukemia (ALL) survivors. Method The study cohort consisted of 86 patients (42 females) previously treated for ALL. The median time after cessation of treatment was 6.55 (IQR: 1.96–9.93) years and median age at the time of study: 12 (IQR: 6.76–16.00). The control group included 53 healthy peers. Immunoenzymatic ELISA commercial kits were used to measure urine KIM-1 and NGAL levels. Results The median levels of urine uNGAL (p < 0.05), uNGAL/creatinine (cr.) ratio ( p < 0.0001) and uKIM-1/creatinine ratio ( p < 0.0001) were significantly higher in ALL survivors in comparison with healthy controls. Female patients had significantly higher levels of NGAL and NGAL/cr. than males (mean 8.42 ± 7.1 vs. 4.59 ± 4.5 ng/mL and 86.57 ± 77 vs. 37.7 ± 37 ng/mg, respectively; p < 0.01). Of all the study participants, 11 (13%) presented eGFR below 90 mL/min/1.73 m 2 . The NGAL/cr. ratio seemed to be the best predictor of decreased eGFR (AUC = 0.65). The cumulative dose of methotrexate and cyclophosphamide did not predict the values of the urine NGAL, NGAL/cr., KIM-1/cr. and eGFR. Five years after the end of treatment, the patients had higher levels of uKIM-1 (1.02 ± 0.8 vs. 0.62 ± 0.6 ng/mL, p < 0.01), uNGAL (7.9 ± 6.7 vs. 4.6 ± 5 ng/mL, p < 0.01) and lower eGFR (114 ± 29 vs. 134 ± 35 mL/min/1.73 m 2 , p < 0.01) in comparison with ALL survivors with the observation period of less than 5 years. Conclusion We demonstrated that ALL survivors have higher levels of urine NGAL , NGAL/cr. and uKIM-1/cr. ratio as compared to the control group. Further long-term follow-up studies are necessary to assess the significance of the NGAL and KIM-1 and their relationship to kidney damage after anticancer treatment in childhood." @default.
• W3092617122 created "2020-10-15" @default.
• W3092617122 creator A5017642619 @default.
• W3092617122 creator A5024812480 @default.
• W3092617122 creator A5030963632 @default.
• W3092617122 creator A5032725451 @default.
• W3092617122 creator A5054207725 @default.
• W3092617122 creator A5061924630 @default.
• W3092617122 creator A5070341654 @default.
• W3092617122 date "2020-10-14" @default.
• W3092617122 modified "2023-09-24" @default.
• W3092617122 title "Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors" @default.
• W3092617122 cites W1510826654 @default.
• W3092617122 cites W1862264719 @default.
• W3092617122 cites W1973652362 @default.
• W3092617122 cites W1976968447 @default.
• W3092617122 cites W2007348709 @default.
• W3092617122 cites W2037795169 @default.
• W3092617122 cites W2044358251 @default.
• W3092617122 cites W2044999311 @default.
• W3092617122 cites W2045082503 @default.
• W3092617122 cites W2056094992 @default.
• W3092617122 cites W2074313484 @default.
• W3092617122 cites W2078211845 @default.
• W3092617122 cites W2080109579 @default.
• W3092617122 cites W2084312498 @default.
• W3092617122 cites W2100630464 @default.
• W3092617122 cites W2107588545 @default.
• W3092617122 cites W2116802079 @default.
• W3092617122 cites W2125690161 @default.
• W3092617122 cites W2156042051 @default.
• W3092617122 cites W2159085968 @default.
• W3092617122 cites W2320438909 @default.
• W3092617122 cites W2467999653 @default.
• W3092617122 cites W2471467307 @default.
• W3092617122 cites W2497055925 @default.
• W3092617122 cites W2539216851 @default.
• W3092617122 cites W2545234811 @default.
• W3092617122 cites W2601958987 @default.
• W3092617122 cites W2605522093 @default.
• W3092617122 cites W2605744525 @default.
• W3092617122 cites W2607407223 @default.
• W3092617122 cites W2732089561 @default.
• W3092617122 cites W2742811155 @default.
• W3092617122 cites W2775293762 @default.
• W3092617122 cites W2780399894 @default.
• W3092617122 cites W2883618301 @default.
• W3092617122 cites W2887125757 @default.
• W3092617122 cites W2893956108 @default.
• W3092617122 cites W2905047249 @default.
• W3092617122 cites W2919905075 @default.
• W3092617122 cites W2982936776 @default.
• W3092617122 cites W3011456484 @default.
• W3092617122 doi "https://doi.org/10.1007/s00280-020-04164-3" @default.
• W3092617122 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7603460" @default.
• W3092617122 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33052454" @default.
• W3092617122 hasPublicationYear "2020" @default.
• W3092617122 type Work @default.
• W3092617122 sameAs 3092617122 @default.
• W3092617122 citedByCount "6" @default.
• W3092617122 countsByYear W30926171222021 @default.
• W3092617122 countsByYear W30926171222022 @default.
• W3092617122 countsByYear W30926171222023 @default.
• W3092617122 crossrefType "journal-article" @default.
• W3092617122 hasAuthorship W3092617122A5017642619 @default.
• W3092617122 hasAuthorship W3092617122A5024812480 @default.
• W3092617122 hasAuthorship W3092617122A5030963632 @default.
• W3092617122 hasAuthorship W3092617122A5032725451 @default.
• W3092617122 hasAuthorship W3092617122A5054207725 @default.
• W3092617122 hasAuthorship W3092617122A5061924630 @default.
• W3092617122 hasAuthorship W3092617122A5070341654 @default.
• W3092617122 hasBestOaLocation W30926171221 @default.
• W3092617122 hasConcept C126189478 @default.
• W3092617122 hasConcept C126322002 @default.
• W3092617122 hasConcept C126894567 @default.
• W3092617122 hasConcept C197934379 @default.
• W3092617122 hasConcept C20299238 @default.
• W3092617122 hasConcept C2776694085 @default.
• W3092617122 hasConcept C2776755627 @default.
• W3092617122 hasConcept C2778653478 @default.
• W3092617122 hasConcept C2780026642 @default.
• W3092617122 hasConcept C2780091579 @default.
• W3092617122 hasConcept C2780306776 @default.
• W3092617122 hasConcept C2780472472 @default.
• W3092617122 hasConcept C71924100 @default.
• W3092617122 hasConcept C77411442 @default.
• W3092617122 hasConcept C90924648 @default.
• W3092617122 hasConceptScore W3092617122C126189478 @default.
• W3092617122 hasConceptScore W3092617122C126322002 @default.
• W3092617122 hasConceptScore W3092617122C126894567 @default.
• W3092617122 hasConceptScore W3092617122C197934379 @default.
• W3092617122 hasConceptScore W3092617122C20299238 @default.
• W3092617122 hasConceptScore W3092617122C2776694085 @default.
• W3092617122 hasConceptScore W3092617122C2776755627 @default.
• W3092617122 hasConceptScore W3092617122C2778653478 @default.
• W3092617122 hasConceptScore W3092617122C2780026642 @default.
• W3092617122 hasConceptScore W3092617122C2780091579 @default.
• W3092617122 hasConceptScore W3092617122C2780306776 @default.

• next